financetom
Business
financetom
/
Business
/
ResMed Fiscal Q1 Non-GAAP Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ResMed Fiscal Q1 Non-GAAP Earnings, Revenue Rise
Oct 30, 2025 1:41 PM

04:25 PM EDT, 10/30/2025 (MT Newswires) -- ResMed ( RMD ) reported fiscal Q1 non-GAAP earnings late Thursday of $2.55 per diluted share, up from $2.20 per share a year earlier.

Analysts polled by FactSet expected $2.52 per share.

Revenue for the quarter ended Sept. 30 was $1.34 billion, up from $1.22 billion a year earlier.

Analysts surveyed by FactSet expected $1.33 billion.

The company kept its quarterly dividend at $0.60 per share, payable Dec. 18 to shareholders of record on Nov. 13.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Comcast Business to Acquire Connectivity Services Provider Nitel From Cinven
Comcast Business to Acquire Connectivity Services Provider Nitel From Cinven
Dec 11, 2024
01:33 PM EST, 12/11/2024 (MT Newswires) -- Comcast ( CMCSA ) subsidiary Comcast Business said Wednesday it has agreed to acquire Nitel, a Chicago-based connectivity services provider, from private equity firm Cinven. Financial details weren't disclosed. Nitel provides network-as-a-service and managed solutions to 6,600 US enterprise customers in financial services, healthcare, and education industries. Price: 39.70, Change: +0.17, Percent Change:...
What's Going On With Moleculin Biotech Shares Wednesday?
What's Going On With Moleculin Biotech Shares Wednesday?
Dec 11, 2024
Moleculin Biotech, Inc. ( MBRX ) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model. What To Know: The preclinical data suggests that Annamycin effectively targets acute myeloid leukemia (AML) cell lines resistant to Cytarabine (Ara-C) and Venetoclax (VEN) in lab tests using cells from patients...
Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia
Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia
Dec 11, 2024
01:33 PM EST, 12/11/2024 (MT Newswires) -- Moleculin Biotech's ( MBRX ) shares were up nearly 9% in recent Wednesday trading after the company announced preclinical data showcasing its drug candidate Annamycin's efficacy against venetoclax-resistant acute myeloid leukemia, or AML, cell lines. Presented at the American Society of Hematology's Annual Meeting, the study showed that Annamycin effectively targets Cytarabine, or...
Sector Update: Consumer
Sector Update: Consumer
Dec 11, 2024
01:30 PM EST, 12/11/2024 (MT Newswires) -- Consumer stocks were mixed Wednesday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) fractionally lower and the Consumer Discretionary Select Sector SPDR Fund (XLY) rising 1.6%. In corporate news, Albertsons ( ACI ) terminated its planned $25 billion acquisition by Kroger ( KR ) after two courts ruled to block the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved